September 2018

SYNSIGHT is proud to announce the launch of a state-of-the-art structural/biophysics unit within the company. Our native AI-powered Computer-Aided Drug Discovery (CADD) expertise and this new experimental unit will enable us to lead integrated drug discovery programs, from virtual screening to experimental validation. This unit will be built and managed by just hired in September, Nicolas Babault, former team leader at the Icahn School of Medicine at Mount Sinai – New York City.